<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">94548</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Macronodular bilateral adrenal hyperplasia: diagnose the aberrant receptors and current aspects of treatment</article-title><trans-title-group xml:lang="ru"><trans-title>Макронодулярная двусторонняя гиперплазия надпочечников: диагностика аберрантных рецепторов и современные аспекты лечения</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Yukina</surname><given-names>M. Yu</given-names></name><name xml:lang="ru"><surname>Юкина</surname><given-names>М. Ю</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. мед. наук, врач первой категории, ст. науч. сотр. отд-ния терапии с группой ожирения ФГБУ ЭНЦ</p></bio><email>kuronova@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Nuralieva</surname><given-names>N. F</given-names></name><name xml:lang="ru"><surname>Нуралиева</surname><given-names>Н. Ф</given-names></name></name-alternatives><bio xml:lang="ru"><p>клин. ординатор ФГБУ ЭНЦ</p></bio><email>Nnurana@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Beltsevich</surname><given-names>D. G</given-names></name><name xml:lang="ru"><surname>Бельцевич</surname><given-names>Д. Г</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед. наук, глав. науч. сотр. отд-ния хирургии ФГБУ ЭНЦ</p></bio><email>belts67@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Troshina</surname><given-names>E. A</given-names></name><name xml:lang="ru"><surname>Трошина</surname><given-names>Е. А</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед. наук, проф., зав. отд-нием терапии с группой ожирения ФГБУ ЭНЦ</p></bio><email>troshina@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Platonova</surname><given-names>N. M</given-names></name><name xml:lang="ru"><surname>Платонова</surname><given-names>Н. М</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед. наук, врач высшей категории, глав. науч. сотр. отд-ния терапии с группой ожирения ФГБУ ЭНЦ</p></bio><email>doc-platonova@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Endocrinology Research Center of the Ministry of Health of the Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБУ Эндокринологический научный центр Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2016-10-15" publication-format="electronic"><day>15</day><month>10</month><year>2016</year></pub-date><volume>18</volume><issue>10</issue><issue-title xml:lang="en">VOL 18, NO10 (2016)</issue-title><issue-title xml:lang="ru">ТОМ 18, №10 (2016)</issue-title><fpage>29</fpage><lpage>33</lpage><history><date date-type="received" iso-8601-date="2021-12-28"><day>28</day><month>12</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2016, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2016, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/94548">https://consilium.orscience.ru/2075-1753/article/view/94548</self-uri><abstract xml:lang="en"><p>The investigation strategy for identification the specific expression of aberrant receptors includes ligand-induced tests. The identification of aberrant receptors provides an opportunity for new pharmacological therapeutic strategies. However, the specific aberrant receptors antagonists administration is limited due to the insufficient data on the effectiveness of medication, and side effects of drugs. Currently there is no unified approach of the management of patients with MBAH. Thus, researches, including genomic, directed at improvement of timely diagnostics of disease and development of new therapeutic and potentially preventive measures against MBAH, are topical.</p></abstract><trans-abstract xml:lang="ru"><p>Статья, посвященная патогенезу и генетическим аспектам макронодулярной двусторонней гиперплазии надпочечников, была опубликована в журнале ≪Consilium Medicum≫, №1, том 18, 2016. Для диагностики аберрантных рецепторов у больных макронодулярной двусторонней гиперплазией надпочечников (МДГН) перспективно проведение лигандиндуцированных тестов. С учетом специфики выявленных рецепторов возможно назначение консервативной терапии. Однако использование специфических антагонистов аберрантных рецепторов ограничено недостаточным количеством данных о эффективности медикаментозного лечения, а также побочными эффектами лекарственных препаратов. Таким образом, в настоящее время не выработана единая тактика ведения пациентов с МДГН. Актуально проведение исследований, в том числе геномных, направленных на усовершенствование своевременной диагностики заболевания, разработку новых терапевтических и потенциально профилактических мер в отношении МДГН.</p></trans-abstract><kwd-group xml:lang="en"><kwd>macronodular bilateral adrenal hyperplasia</kwd><kwd>diagnose the aberrant membrane receptors</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>макронодулярная двусторонняя гиперплазия надпочечников</kwd><kwd>диагностика аберрантных мембранных рецепторов</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Louiset E, Lefebvre H. Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia. N Engl J Med 2014; 370 (11): 1071-2.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Cavagnini F, Giraldi F.P. Adrenal Causes of Cushing’s Syndrome. In: Jameson J.L, De Groot L.G, editors. Endocrinology: Adult and Pediatric. 7th Edition. 2015; р. 1775-809.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Lacroix A, Ndiaye N, Tremblay J, Hamet P. Ectopic and abnormal hormone receptors in adrenal Cushing’s syndrome. Endocr Rev 2001; 22: 75-110.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Elbelt U, Trovato A, Kloth M. Molecular and clinical evidence for an ARMC5 tumor syndrome: concurrent inactivating germline and somatic mutations are associated with both primary macronodular adrenal hyperplasia and meningioma. J Clin Endocrinol Metab 2015; 100 (1): E119-28.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Lacroix A, Costa M.H.S. Cushing’s Syndrome Secondary to ACTH-Independent Macronodular Adrenal Hyperplasia. Arq Bras Endocrinol Metab 2007; 51 (8): 1226-37.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Albiger N.M, Occhi G, Mariniello В et al. Food - dependent Cushing’s syndrome: from molecular characterization to therapeutical results. Eur J Endocrinol 2007; 157 (6): 771-8.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Christopoulos S, Bourdeau I, Lacroix A. Clinical and subclinical ACTH-independent macronodular adrenal hyperplasia and aberrant hormone receptors. Horm Res 2005; 64 (3): 119-31.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Christopoulos S, Bourdeau I, Lacroix A. Aberrant Expression of Hormone Receptors in Adrenal Cushing's Syndrome. Pituitary 2004; 7 (4): 225-35.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Fujii H, Tamamori-Adachi M, Uchida K et al. Marked Cortisol Production by Intracrine ACTH in GIPTreated Cultured Adrenal Cells in Which the GIP Receptor Was Exogenously Introduced. PLOS ONE 2014; 9 (10).</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Tock L, Carneiro G, Pereira A.Z et al. Adrenocortical Production Is Associated with Higher Levels of Luteinizing Hormone in Nonobese Women with Polycystic Ovary Syndrome. Int J Endocrinol 2014.</mixed-citation></ref></ref-list></back></article>
